Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

Fizazi, K. et al. (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncology, 13(10), pp. 983-992. (doi: 10.1016/S1470-2045(12)70379-0)

Full text not currently available from Enlighten.


Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Jones, Professor Robert
Authors: Fizazi, K., Scher, H.I., Molina, A., Logothetis, C.J., Chi, K.N., Jones, R.J., Staffurth, J.N., North, S., Vogelzang, N.J., Saad, F., Mainwaring, P., Harland, S., Goodman, O.B., Sternberg, C.N., Li, J.H., Kheoh, T., Haqq, C.M., and de Bono, J.S.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:Lancet Oncology
ISSN:1470-2045

University Staff: Request a correction | Enlighten Editors: Update this record